Cas:119774-74-2 1-(2-fluoro-4-propoxyphenyl)ethanone manufacturer & supplier

Chemical Name:1-(2-fluoro-4-propoxyphenyl)ethanone

CAS.NO:119774-74-2

Synonyms:PC8851;1-acetyl-2-fluoro-4-propoxybenzene;2′-Fluoro-4′-propoxyacetophenone

Molecular Formula:C₁₁H₁₃FO₂

Molecular Weight:196.21800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:277.2ºC at 760 mmHg

Density:1.077g/cm3

Index of Refraction:1.485

PSA:26.30000

Exact Mass:196.09000

LogP:2.81710

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like PC8851 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2′-Fluoro-4′-propoxyacetophenone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2′-Fluoro-4′-propoxyacetophenone Use and application,PC8851 technical grade,usp/ep/jp grade.

Related News: Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations. 1-(2-fluoro-4-propoxyphenyl)ethanone manufacturer Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality. 1-(2-fluoro-4-propoxyphenyl)ethanone supplier Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations. 1-(2-fluoro-4-propoxyphenyl)ethanone vendor Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality. 1-(2-fluoro-4-propoxyphenyl)ethanone factory Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.